

MEDIA RELEASE

Date 16 September 2008
Subject Venofer®: Closing of the agreement between Fresenius Medical Care and Luitpold Pharmaceuticals, Inc.

((for public release on 16 September 2008, 7.30 a.m. CET))

Venofer®: Closing of the US license agreement between Fresenius Medical Care and Luitpold Pharmaceuticals, Inc.

Fresenius Medical Care and Luitpold Pharmaceuticals, Inc. have closed an exclusive license agreement covering the marketing and distribution of Venofer® for use in dialysis treatment in the US and Canadian markets. The closing of this agreement follows completion of the US Federal Trade Commission's (FTC) review of the license agreement under the Hart-Scott-Rodino Antitrust Act and the issuance of a consent order to permit the closing.

In July 2008, Galenica Ltd., its subsidiary Vifor Pharma and Fresenius Medical Care, the world's largest provider of dialysis products and services, entered into a strategic joint venture to market and distribute its iron products Venofer® and Ferinject® for use in dialysis treatment in Europe, the Middle East, Africa and Latin America.

In the U.S. and Canada Galenica exclusively licenses Venofer® and Injectafer® (US brand name for Ferinject®) to Luitpold Pharmaceuticals, Inc., who have entered into a corresponding sublicense agreement with Fresenius Medical Care. The agreement covers the manufacture and distribution of Venofer® for dialysis in the US and Canadian markets. In addition, the agreement includes a similar sublicense for Injectafer® (US brand name for Ferinject®). Luitpold will continue to sell Venofer® outside the field of dialysis for use in treating chronic kidney disease patients who are not yet on dialysis and patients with acute renal failure in hospitals.

Venofer® is the leading intravenous (I.V.) iron product worldwide and is regarded as the gold standard in dialysis. Ferinject® is a new I.V. iron product with which Galenica aims to extend the parenteral iron market beyond haemodialysis into new indications.

For further information:

Investor Relations:
Fritz Hirsbrunner, CFO
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

Media Relations:
Christina Hertig, Head of Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Galenica Ltd.
Untermattweg 8 · P.O. Box · CH-3001 Berne
Tel. +41 58 852 85 17 · Fax +41 58 852 85 58
media@galenica.com · www.galenica.com

Date 16 September 2008

Page 2

Subject Venofer[®]: Closing of the agreement between Fresenius Medical Care and Luitpold Pharmaceuticals, Inc.

Galenica is a diversified group active throughout the healthcare market which, among other things, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. The Galenica Group enjoys a leading position in all its business sectors – Pharma, Logistics, HealthCare Information and Retail. A large part of the Group's income is generated by international operations.

Additional information on the Galenica Group can be found at www.galenica.com.

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,600,000 individuals worldwide. Through its network of 2,318 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 180,000 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

Luitpold Pharmaceuticals, Inc. Luitpold Pharmaceuticals, Inc., headquartered in Shirley, NY, manufactures and distributes over 65 pharmaceutical products including Venofer[®] (iron sucrose injection, USP), the leading IV iron therapy in the U.S., through its human health subsidiary, American Regent, Inc. Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo group company, also markets dental bone regeneration products and veterinary pharmaceuticals through its Osteohealth and Animal Health divisions. Daiichi Sankyo Company, Ltd., established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world.

For more information about Luitpold see www.luitpold.com.